Stockscreener 앱 받기
31.20
3.91%
-1.27
시간 외 거래:
31.20
전일 마감가:
$32.47
열려 있는:
$32.32
하루 거래량:
1.12M
Relative Volume:
1.74
시가총액:
$3.85B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-25.23%
1개월 성능:
-20.47%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$29.57
$32.32
1주일 범위
$29.57
$42.31
52주 변동 폭
$24.51
$42.48
Parabilis Medicines Inc Stock (PBLS) Company Profile
Compare PBLS vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PBLS
Parabilis Medicines Inc
|
31.20 | 3.85B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Parabilis Medicines Inc 주식(PBLS)의 최신 뉴스
PBLS Price Today: Parabilis Medicines, Inc. Stock Price, Quote & Chart | MEXC - mexc.co
Top Parabilis Medicines (PBLS) Competitors 2026 - MarketBeat
Parabilis Medicines (NASDAQ:PBLS) Stock Price Down 6.3%What's Next? - MarketBeat
Parabilis Medicines, Inc.(NasdaqGS: PBLS) added to S&P TMI Index - marketscreener.com
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Biotech Stocks At 52-Week HighsMNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO - RTTNews
Parabilis Medicines, Inc.(NasdaqGS: PBLS) added to Russell 3000 Growth Index - marketscreener.com
Parabilis Medicines (NASDAQ:PBLS) Hits New 52-Week HighTime to Buy? - MarketBeat
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating, Announces Target Price $45 - Moomoo
48,484 Shares in Parabilis Medicines, Inc. $PBLS Acquired by Squarepoint Ops LLC - MarketBeat
PBLS: Zolucatetide advances as a multi-indication therapy, with strong data and broad pipeline expansion - TradingView
Parabilis at Morgan Stanley conference: broad bet on beta-catenin - Investing.com
PBLS: Zolucatetide's clinical progress and platform innovation drive a broad pipeline and major upcoming milestones - TradingView
Parabilis Medicines (NASDAQ:PBLS) Trading Up 6%Still a Buy? - MarketBeat
Parabilis Medicines to Showcase Updated Zolucatetide Trial Results at ESMO 2026 - Kalkine Media
WINTON GROUP Ltd Takes Position in Parabilis Medicines, Inc. $PBLS - marketbeat.com
Parabilis Medicines (PBLS) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
1,920,805 Shares in Parabilis Medicines, Inc. $PBLS Purchased by Frazier Life Sciences Management L.P. - MarketBeat
Parabilis Medicines, Inc. Common Stock (NASDAQ: PBLS) Stock Price, News & Analysis - Kalkine
Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewswire
ICONIQ Capital LLC Takes $9.58 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Regeneron Pharmaceuticals Inc. Buys New Stake in Parabilis Medicines, Inc. $PBLS - MarketBeat
1,600,937 Shares in Parabilis Medicines, Inc. $PBLS Purchased by General Catalyst Group Management LLC - MarketBeat
venBio Partners LLC Takes $144.15 Million Position in Parabilis Medicines, Inc. $PBLS - MarketBeat
Jupiter Topco LLC Buys Shares of 2,296,547 Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Parabilis appoints Craig Tendler to its Board and Science & Technology Committee - TradingView
Parabilis Medicines adds former J&J oncology executive to board By Investing.com - Investing.com Canada
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors - finance.yahoo.com
ICONIQ Capital LLC Makes New Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
Parabilis Medicines Price Insights - YCharts
Parabilis Medicines (NASDAQ:PBLS) Stock Price Up 5.9%Here's What Happened - MarketBeat
Alphabet Inc. Makes New $134.65 Million Investment in Parabilis Medicines, Inc. $PBLS - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Biotech’s reverse merger renaissance poised to continue - Endpoints News
Parabilis Medicines (NASDAQ:PBLS) Sets New 1-Year HighWhat's Next? - MarketBeat
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS) - The Globe and Mail
Parabilis Medicines(PBLS) Stock Options Chain | Quotes & News - Moomoo
Parabilis Medicines Inc. (PBLS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Parabilis Medicines (PBLS): ARCH Venture group discloses 6.4M-share, 5.3% ownership - Stock Titan
BofA Securities Maintains Parabilis Medicines(PBLS.US) With Buy Rating - Moomoo
Parabilis Medicines: A Rare-Tumor Validation Ladder For An Undruggable Platform (NASDAQ:PBLS) - Seeking Alpha
PBLS SWOT Analysis: Financial Resilience Amidst Clinical Challen - GuruFocus
Parabilis Medicines (PBLS) Earnings Date and Reports 2026 - MarketBeat
Parabilis Medicines: Q2 Earnings Snapshot - AOL.com
Parabilis Medicines (PBLS) boosts cash above $1.1B after IPO and Regeneron deal - Stock Titan
Form 8K Parabilis Medicines For: 13 August By Investing.com - Investing.com Nigeria
PBLS: Lead asset zolucatetide shows strong efficacy and safety, driving a robust pipeline and growth - TradingView
Parabilis Medicines Q2 Loss Narrows; Shares Rise Pre-Bell - marketscreener.com
Earnings Flash (PBLS) Parabilis Medicines Posts Q2 Net Loss $2.32 a Share - marketscreener.com
Parabilis Medicines Inc (PBLS) 재무 분석
Parabilis Medicines Inc (PBLS)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):